MASLD Cases Surge Globally

A study published in The Lancet Gastroenterology and Hepatology, led by the Institute for Health Metrics and Evaluation at the University of Washington, revealed that 1.3 billion people globally were living with Metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, a 143% increase since 1990. Projections indicate this number could rise to 1.8 billion by 2050, driven by population growth, obesity, and high blood sugar levels. While treatment advancements have stabilized the overall disease burden, the expanding patient pool poses a long-term risk of severe complications like liver cirrhosis and cancer. Regions such as North Africa and West Asia show disproportionately higher rates, and countries like the United Kingdom, Australia, and the United States have seen significant increases in prevalence. The study emphasizes the need for global recognition of MASLD as a health priority and for targeted interventions.